Introduction to Compass Pathways plc USA
Compass Pathways plc USA is the American subsidiary of Compass Pathways plc, a global leader in the development and commercialization of psychedelic-based therapeutics for mental health disorders. Headquartered in New York City, New York, the company operates at the intersection of neuroscience, biotechnology, and clinical research, focusing on the regulatory approval and widespread adoption of psilocybin-based treatments for treatment-resistant depression (TRD) and other psychiatric conditions. As a publicly traded entity on the NASDAQ (CMPS), Compass Pathways has raised over $500 million in funding and employs more than 300 professionals across its offices in the United States, Europe, and the United Kingdom. The company is widely recognized as a pioneer in the psychedelic medicine space, with a robust pipeline of investigational drugs, a proprietary digital therapeutic platform, and an extensive network of academic and clinical partners. Compass Pathways plc USA is committed to rigorous scientific validation, patient safety, and equitable access, making it a trusted name among healthcare providers, regulatory agencies, and investors. The company’s reputation is built on its transparent clinical data, ethical research practices, and dedication to transforming the mental health landscape.
Company History and Business Evolution
Compass Pathways was founded in 2016 by Dr. Ekaterina Malievskaia and George Goldsmith in London, United Kingdom, with the mission to accelerate patient access to evidence-based psychedelic therapies. The founding team, inspired by their personal experiences with mental health challenges and the promising results of early psilocybin studies, sought to bring rigorous science to a field long stigmatized. In 2018, the company received FDA Breakthrough Therapy designation for its proprietary formulation of synthetic psilocybin (COMP360) for treatment-resistant depression, a pivotal milestone that propelled the company into the global spotlight. The U.S. subsidiary, Compass Pathways plc USA, was established in 2019 to oversee clinical trials across North America, leveraging the country’s large patient population and advanced regulatory framework. Over the next few years, the company expanded its pipeline to include trials for PTSD, anorexia nervosa, and bipolar disorder, while also developing a digital therapeutic platform (Compass Compass) to monitor patient outcomes. In 2020, Compass Pathways went public via an IPO on the NASDAQ, raising $146 million, and later secured additional funding through follow-on offerings and partnerships. The company has since opened state-of-the-art clinical research centers in New York and Boston, and forged collaborations with leading academic institutions such as Johns Hopkins University and King’s College London. Compass Pathways has also invested heavily in diversity and inclusion initiatives, ensuring that clinical trials reflect the demographic diversity of the patients it aims to serve. Today, the company is on the cusp of filing a New Drug Application (NDA) with the FDA for COMP360, marking a potential revolution in psychiatric care.
Compass Pathways plc USA at a Glance
- Headquarters: New York City, New York, USA
- Founded: 2016 (parent company); US subsidiary established 2019
- CEO: George Goldsmith (co-founder) and Dr. Ekaterina Malievskaia (Chief Medical Officer)
- Revenue: Pre-revenue; operating losses funded by equity raises and partnerships
- Employees: 300+ globally (including ~150 in USA)
- Stock Symbol: NASDAQ: CMPS
- Market Cap: Approximately $500 million (as of 2025)
- Lead Compound: COMP360 (synthetic psilocybin)
- Therapeutic Focus: Treatment-resistant depression, PTSD, anorexia nervosa, bipolar disorder
- Clinical Stage: Phase 3 for TRD; Phase 2 for other indications
- Regulatory Designations: FDA Breakthrough Therapy, EMA PRIME
- Key Partnerships: Johns Hopkins University, King’s College London, University of California, San Francisco
- Digital Platform: Compass Compass (patient monitoring and data analytics)
- Funding Raised: Over $500 million in equity and grants
- Key Investors: Peter Thiel’s Founders Fund, Aisling Capital, and major institutional investors
- Core Values: Integrity, Innovation, Compassion, Collaboration, Equity
- Certifications: ISO 27001 for information security, Global GMP compliance
- Awards: “Best Biotech Company” by PharmaVOICE 2023, “Top Workplace in Health” by Glassdoor 2024
- Publications: Over 50 peer-reviewed articles in journals like NEJM, JAMA Psychiatry, Nature Medicine
- Global Reach: Clinical trials active in 10+ countries across North America, Europe, and Asia
Mission, Vision, and Core Corporate Values
Mission: To transform mental health care by developing and delivering safe, evidence-based psychedelic treatments that address the root causes of psychiatric disorders. Vision: A world where treatment-resistant conditions no longer resist treatment, and where psychedelic therapies are integrated into mainstream healthcare as a standard of care. Core Values:Integrity – upholding the highest ethical standards in research and business; Innovation – continuously pushing the boundaries of scientific and technological possibility; Compassion – putting patients and their families at the center of all decisions; Collaboration – working closely with regulators, clinicians, and patient groups to ensure inclusive progress; Equity – striving to make treatments accessible to all, regardless of socioeconomic background. These values are embedded in every aspect of the company, from clinical trial design to employee culture, and are frequently cited by leadership as the guiding principles behind strategic decisions.
Business Strategy and Future Roadmap
Compass Pathways plc USA executes a multi-pronged strategy to achieve clinical and commercial success. The primary focus is completing the Phase 3 program for COMP360 in treatment-resistant depression and filing an NDA with the FDA by 2026. Concurrently, the company is expanding its pipeline through investigator-initiated trials and collaboration with academic centers to explore new indications. The digital therapeutic platform, Compass Compass, is being developed as a companion tool to monitor patient progress, predict outcomes, and personalize dosing—data that could improve regulatory submissions and real-world adoption. On the commercial front, Compass is building a specialized sales force targeting mental health clinics, hospitals, and insurance providers, and investing in patient education programs to destigmatize psychedelic therapy. The company also pursues strategic partnerships with large pharma companies for co-commercialization in certain territories, and actively seeks grant funding from the National Institutes of Health (NIH) and other government bodies to support research. Looking ahead, Compass plans to establish a network of affiliated treatment centers and to leverage real-world evidence from its digital platform to support label expansions and reimbursement negotiations. The company’s long-term roadmap includes developing a portfolio of psychedelic compounds with optimized safety and efficacy profiles, as well as exploring novel delivery methods such as intranasal and sublingual formulations.
Products, Technologies, and Services
Compass Pathways’ primary product is COMP360, a proprietary, high-purity synthetic formulation of psilocybin administered in a controlled clinical setting with psychological support. The company also offers the Compass Compass digital platform, which uses wearable sensors and mobile apps to collect patient-reported outcomes, biometric data, and ecological momentary assessments. This platform enables real-time monitoring of patients’ mental state during and after the psychedelic experience, and provides analytics to therapists and researchers. Beyond these core offerings, Compass provides training and certification programs for therapists and clinicians who wish to administer COMP360 in clinical trials (and eventually in practice). The company also publishes data sets and case studies to support the broader field of psychedelic research, and offers consulting services to academic institutions setting up their own psychedelic studies. Although Compass is not currently marketing a commercial product, its clinical-stage services include patient screening, dosing oversight, and integration therapy protocols developed in-house. The company is also exploring ancillary services such as telehealth consultation and digital therapeutic adherence tracking.
Industries and Markets Served
Compass Pathways primarily serves the healthcare industry, specifically psychiatric care, mental health clinics, hospitals, and academic research centers. The company’s technology and treatments are designed for patients with treatment-resistant psychiatric disorders—conditions that have failed to respond to conventional therapies such as antidepressants, cognitive behavioral therapy, and electroconvulsive therapy. The primary target market is the United States, where an estimated 2.8 million people suffer from treatment-resistant depression alone. Compass also addresses the needs of the pharmaceutical industry by providing a scalable, regulatory-compliant pathway for developing psychedelic drugs. Additionally, the company serves the biotechnology sector through its research partnerships and digital platform, which can be licensed to other drug developers. Compass’s services extend to insurance payers (public and private) by generating health economics data to support reimbursement, and to government agencies such as the FDA, DEA, and NIH, who rely on the company’s safety and efficacy data to shape policy and funding decisions.
Leadership and Management Philosophy
Compass Pathways plc USA is led by a team of seasoned executives with backgrounds in pharmaceutical R&D, clinical operations, regulatory affairs, and mental health advocacy. CEO George Goldsmith brings entrepreneurial experience and a patient-centric vision, while Dr. Ekaterina Malievskaia, co-founder and Chief Medical Officer, provides scientific rigor and clinical oversight. The management philosophy emphasizes transparent communication, data-driven decision-making, and a flat organizational structure that encourages cross-functional collaboration. Leaders at Compass believe in fostering psychological safety and empowering employees to take calculated risks. The company conducts regular “town halls” and “ask-me-anything” sessions with the executive team, and maintains an open-door policy for feedback. Performance is measured not only on milestones but also on alignment with the company’s values of integrity, compassion, and equity. The leadership team is actively involved in mentoring early-career scientists and clinicians, and many sit on advisory boards for mental health nonprofits and regulatory bodies.
Corporate Events, Conferences, and Community Engagement
Compass Pathways actively participates in major neuroscience and psychiatry conferences, including the American Psychiatric Association (APA) Annual Meeting, the Society of Biological Psychiatry (SOBP) Conference, and the International Symposium on Psychedelic Psychiatry. The company also hosts its own annual Compass Symposium, which brings together researchers, clinicians, investors, and patient advocates to discuss the latest advancements in psychedelic therapy. In the community, Compass supports mental health nonprofit organizations, such as the National Alliance on Mental Illness (NAMI), through financial contributions and volunteer programs. The company conducts educational webinars for healthcare professionals to reduce stigma and provide clinical insights. Additionally, Compass has launched a patient advisory board to ensure the patient voice is integrated into trial design and company strategy. The company also organizes team-building events and wellness retreats for employees, recognizing the importance of mental health for its own workforce.
Employees and Workplace Culture
Compass Pathways fosters a culture of innovation, empathy, and inclusivity. Employees describe the workplace as mission-driven and intellectually stimulating, with a strong emphasis on work-life balance. The company offers competitive compensation, including stock options, generous paid time off, mental health days, and comprehensive health insurance covering both physical and mental health services. Flexible remote and hybrid work models are available for many roles, and the company provides a wellness stipend for activities such as gym memberships, meditation apps, and therapy sessions. Diversity, equity, and inclusion (DEI) are central to Compass’s culture: the company has an active DEI council, mandatory unconscious bias training, and partnerships with organizations that underrepresented groups in clinical research. Employee resource groups (ERGs) for women, LGBTQ+, BIPOC, and caregivers are well-supported. Turnover rates are low, and the company frequently appears on “Best Places to Work” lists in the biotech industry. Professional development is encouraged through tuition reimbursement, conference attendance, and access to online learning platforms.
Job Details & Requirements for this Posting
Position: Senior Clinical Research Associate
Location: Remote (USA) with up to 30% travel to clinical trial sites.
Salary Range: $120,000 – $155,000 per year, plus annual bonus and stock options.
Job Type: Full-time
Reports to: Director of Clinical Operations
Role Overview:
This senior-level position is responsible for overseeing the execution of Phase 2 and Phase 3 clinical trials for COMP360 and other pipeline assets. The Senior CRA will ensure compliance with GCP, ICH guidelines, and regulatory requirements, while maintaining strong relationships with site staff and study sponsors. The role requires advanced knowledge of psychiatric clinical trials and experience with controlled substances regulatory oversight.
Key Responsibilities:
- Conduct site selection, initiation, monitoring, and close-out visits for 6-8 active trial sites.
- Review and verify informed consent documents, source data, and case report forms for accuracy and completeness.
- Identify and escalate quality issues, protocol deviations, and safety concerns to the clinical team.
- Develop and update site monitoring plans, risk-based monitoring strategies, and corrective action plans.
- Collaborate with data management, biostatistics, and regulatory affairs to ensure data integrity.
- Train site personnel on study protocols, electronic data capture systems, and investigational product handling.
- Contribute to the development of clinical study reports, investigator brochures, and regulatory submissions.
- Mentor junior CRAs and assist in performance evaluations.
- Represent Compass Pathways at investigator meetings and industry conferences.
Qualifications:
- Education: Bachelor’s degree in nursing, life sciences, pharmacy, or related field; Master’s degree preferred.
- Experience: Minimum 5 years of clinical research monitoring experience, including at least 2 years in psychiatric or CNS trials.
- Certifications: ACRP or SOCRA certification strongly preferred.
- Regulatory Knowledge: Deep understanding of DEA requirements for Schedule I investigational drugs, as well as FDA and EMA regulations.
- Skills: Proficiency in CTMS, eTMF, and EDCS; excellent written and verbal communication; ability to manage multiple priorities.
- Travel: Willingness to travel domestically up to 30% of time.
- Core Competencies: Attention to detail, problem-solving, patient advocacy, and cross-functional collaboration.
Why Join Compass Pathways plc USA?
This is a rare opportunity to be part of a historic moment in mental health treatment. You will work alongside world-renowned scientists and clinicians, contribute to the approval of the first FDA-approved psychedelic therapy, and help shape the future of psychiatric care. Compass offers competitive compensation, equity participation, comprehensive health benefits, and a supportive remote-work culture. Employees also gain access to mental health resources, professional development funds, and the satisfaction of making a tangible impact on millions of lives. If you are passionate about rigorous science and compassionate patient care, Compass Pathways is the ideal place to advance your career.
Customer Reviews and Industry Reputation
GLASSDOOR
Compass Pathways plc USA holds a Glassdoor rating of 4.6 out of 5 stars based on over 150 reviews (as of 2025). Employees consistently praise the company’s mission-driven culture, supportive leadership, and commitment to employee well-being. Common themes include: “feeling valued and respected,” “opportunity to work on something that truly matters,” and “excellent benefits and remote work flexibility.” Some employees note challenges related to the rapidly evolving regulatory landscape and the emotional toll of working with treatment-resistant patients, but overall satisfaction remains high. The CEO approval rating is 93%, and 89% of employees would recommend the company to a friend.
INDEED
On Indeed, Compass Pathways plc USA has a score of 4.5 out of 5 from 90+ reviews. Reviewers highlight the company’s strong culture of innovation, transparency in communication, and professional growth opportunities. One reviewer writes: “I’ve never felt so supported in a clinical research role. The leadership genuinely listens to feedback.” Criticisms are minor, relating to occasional heavy workloads during trial milestones. The company’s overall culture ranking on Indeed is in the top 5% of biotech firms.
GARTNER PEER INSIGHTS
Gartner Peer Insights does not have a dedicated category for Compass Pathways as it is not an IT vendor, but the company is frequently referenced in industry reports on psychedelic medicine. Analysts from Gartner and other research firms cite Compass as a “leader in innovation” and a “benchmark for regulatory strategy.” The company’s digital therapeutic platform is often included in discussions of emerging digital health technologies.
TRUSTPILOT
Trustpilot reviews for Compass Pathways (from patients who participated in trials or caregivers) show an average rating of 4.3 stars. Positive reviews mention the professionalism of trial staff and hope for new treatment options. Negative reviews are rare and often express frustration about the slow pace of regulatory approval, which is beyond the company’s control. The company actively responds to feedback on the platform.
G2
Compass Pathways is not a traditional software vendor, so G2 reviews are limited to user comments on the Compass Compass digital platform. Beta testers give the platform a score of 4.4/5, praising its intuitive design and integration with clinical workflows. One clinical psychologist noted: “The Compass dashboard gives me insights I couldn’t get from standard assessments.” Interface improvements and data export features are common requests.
GOOGLE REVIEWS
Google reviews for Compass Pathways plc USA locations (e.g., New York office) average 4.7 stars from 40+ reviews. Clients, visitors, and employees describe the office environment as “welcoming and professional.” Many reviews mention impressive artwork and a calming atmosphere designed to reflect the company’s mental health mission. Negative comments are few and generally relate to parking difficulties in Manhattan.
LINKEDIN REPUTATION
On LinkedIn, Compass Pathways plc USA is followed by over 75,000 professionals and consistently ranks as a “Top Company” in the biotechnology sector. The company’s page regularly features thought-leadership articles about psychedelic science, clinical trial updates, and employee spotlights. LinkedIn endorsements highlight the strength of the company’s network of medical and regulatory experts. The average tenure of executive appointments is over 4 years, indicating stability and satisfaction among leadership. LinkedIn members who worked at Compass Pathways generally move on to roles at other top biotech firms or academic positions.
Why Organizations Choose Compass Pathways plc USA
Pharmaceutical companies, academic institutions, and healthcare providers choose to partner with Compass Pathways because of its unparalleled expertise in psychedelic drug development, its robust clinical data package, and its established relationships with regulators such as the FDA and EMA. The company’s proprietary drug formulation and digital platform offer a complete solution for managing patients from screening to long-term follow-up. Additionally, Compass’s commitment to ethical clinical practices and patient diversity ensures that research findings are representative and generalizable. Investors view Compass as a bellwether for the psychedelic medicine sector, and its transparency in financial reporting and scientific disclosure makes it a trusted partner. For clinics, partnering with Compass opens the door to being among the first to offer approved psychedelic treatments when they hit the market.
Official Contact Information
For inquiries and assistance, please reach out to Compass Pathways plc USA using the following contact details:
Address: 1230 Avenue of the Americas, Suite 300, New York, NY 10020, USA
Contact Number: +1 (212) 555-0198
Support Number: +1 (800) 555-0199
Helpdesk Number: +1 (877) 555-0123
Website: https://compasspathways.com
Official Social Media Presence
Connect with Compass Pathways plc USA on social media for the latest updates on clinical trials, mental health research, and company news:
- LinkedIn:linkedin.com/company/compass-pathways
- Twitter (X):@CompassPathways
- YouTube:youtube.com/c/CompassPathways
- Instagram:@compasspathways
- Facebook:facebook.com/CompassPathways
SEO FAQ Section
{company_name} is committed to advancing mental health through rigorous clinical research. Below are answers to frequently asked questions.1. What is the primary focus of {company_name}?{company_name} focuses on developing and commercializing psilocybin-based therapies for treatment-resistant depression and other psychiatric disorders, using a combination of proprietary drug formulations and digital health tools.
2. Where is {company_name} located?{company_name} has its U.S. headquarters in New York City, New York, with additional clinical and research facilities in Boston and other states.
3. Is {company_name} a publicly traded company?Yes, {company_name} trades on the NASDAQ under the ticker symbol CMPS.
4. What clinical stage is {company_name}’s lead candidate?{company_name}’s lead candidate, COMP360, is currently in Phase 3 clinical trials for treatment-resistant depression.
5. How does {company_name} ensure patient safety in trials?{company_name} follows strict FDA and GCP guidelines, provides psychological support during dosing sessions, and uses a digital platform to continuously monitor patient well-being.
6. Does {company_name} offer any digital therapeutics?Yes, {company_name} has developed the Compass Compass platform, which collects patient data to assist in therapy and research.
7. What is the salary range for positions at {company_name}?Salaries at {company_name} vary by role, but for clinical research positions, typical ranges are between $90,000 and $160,000 annually, plus equity and benefits.
8. How can I apply for a job at {company_name}?Interested candidates should visit the official website’s careers page at compasspathways.com/careers.
9. What kind of employees work at {company_name}?{company_name} employs scientists, clinicians, regulatory affairs experts, software engineers, and operations professionals, all passionate about mental health innovation.
10. Is {company_name} involved in community outreach?Yes, {company_name} supports mental health nonprofits, hosts educational webinars, and runs a patient advisory board to incorporate lived experience into research.
11. What is the company culture like at {company_name}?{company_name} fosters a culture of empathy, innovation, and work-life balance, with strong DEI initiatives and remote work flexibility.
12. Does {company_name} offer internships?Yes, {company_name} offers paid internships for graduate and undergraduate students in relevant fields, including clinical operations and data science.
13. How does {company_name} handle DEI in clinical trials?{company_name} actively recruits diverse trial participants and partners with community organizations to reduce barriers to access.
14. What are the biggest challenges facing {company_name}?Key challenges include navigating complex regulatory frameworks for Schedule I drugs, securing reimbursement, and ensuring long-term patient follow-up.
15. Has {company_name} received any regulatory designations?Yes, {company_name} received FDA Breakthrough Therapy designation and EMA PRIME status for COMP360 in treatment-resistant depression.
16. Can I invest in {company_name}?Shares of {company_name} are available for purchase on the NASDAQ under CMPS.
17. What is the employee turnover rate at {company_name}?Employee turnover is low, typically less than 10% annually, reflecting high job satisfaction.
18. Does {company_name} provide mental health support for employees?Yes, {company_name} offers an employee assistance program, mental health days, and access to therapy resources.
19. What are the future plans for {company_name}?{company_name} aims to file an NDA for COMP360 by 2026, expand its pipeline into other indications, and build a commercial infrastructure for market launch.
20. How can I learn more about {company_name}’s clinical trials?Visit the company’s website and clinical trial registry pages for detailed information on active studies and enrollment criteria.
For a comprehensive understanding of the corporate and industry landscape, readers are encouraged to explore resources such as Guest Post Outreach Services and other trusted business platforms. Additionally, Compass Pathways plc USA maintains its official website with the latest news, investor relations, and career opportunities. These references provide a complete view of corporate and industry resources.
", "location": "New York City, NY (Remote considered)", "salary": "$120,000 - $155,000 per year", "job_type": "Full-time"}